Alphatec Hlds

Alphatec Holdings, Inc. engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings. The company was founded on March 4, 2005 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alphatec (ATEC) posts robust earnings, eyes growth through innovation

Alphatec (ATEC) delivered strong financial results in Q4 2022, with revenue growth, operational improvements, and a positive outlook for 2023.
The company's focus on innovation, surgeon adoption, and profitability underscores its strategic approach to sustainable growth and market leadership.
ATEC faces challenges in margin improvement, achieving EBITDA targets, and navigating competitive consolidation in the spine space.
However, the company remains optimistic, leveraging opportunities in procedural expansion, technological innovation, and international market expansion for future success.

Alphatec (ATEC) reports stellar Q1 growth and strategic acquisitions

Alphatec (ATEC) showcased robust revenue growth, strategic acquisitions, and a focus on enhancing procedural efficiency and surgeon adoption.
While challenges exist in achieving EBITDA break-even and expanding margins, ATEC's strong performance and growth outlook present promising opportunities.
The company's emphasis on technology integration, international expansion, and increasing robotics utilization positions ATEC for future success.

Alphatec (ATEC) reports robust Q2 growth and eyes international expansion

Alphatec's Q2 performance reflects strong revenue growth, margin expansion, and market share gains driven by strategic initiatives in spine surgery. The company's focus on innovation, surgeon adoption, and geographic expansion positions it well for future growth and success in the spine market.

Alphatec (ATEC) reports robust Q3 earnings, eyes growth opportunities

Alphatec (ATEC) delivered strong financial performance in Q3 2023, driven by revenue growth, positive adjusted EBITDA, and strategic initiatives.
The company's strengths lie in its spine surgery focus, new product launches, and advancements in informatics and robotic integration.
Challenges include managing risks, balancing growth with profitability, and navigating market disruptions, while opportunities exist in expansion and technology integration.

Alphatec (ATEC) reports robust Q4 performance, eyes international expansion

Alphatec (ATEC) had a strong Q4 2023, focusing on clinical excellence and market share growth. Challenges include managing debt and sustaining momentum. Opportunities lie in international expansion and innovative product launches.

Alphatec Hlds (ATEC) reports robust Q1 performance and growth outlook

Alphatec Hlds (ATEC) delivered a strong Q1 2024 performance with significant revenue growth, surgeon adoption, and sales team confidence, underpinned by a focus on innovation and market expansion.
While facing challenges in debt management and profitability, the company's strategic outlook, financial strength, and growth drivers position it well for future success and sustained growth.
By capitalizing on opportunities in technology integration, international expansion, and market share expansion, Alphatec is poised to drive continued innovation and value creation in the spine surgery market.

Alphatec Hlds (ATEC) reports robust Q2 growth and eyes Japan expansion

Alphatec Hlds (ATEC) delivered strong financial results in Q2 2024, showcasing growth in revenue, profitability, and surgeon engagement, while focusing on innovation and clinical distinction.
The company faces challenges in achieving cash flow break-even, entering new markets like Japan, and expanding into deformity surgery, but sees opportunities in market growth and technological advancements.
Overall, Alphatec Hlds (ATEC) remains committed to advancing spine surgery through technology, attracting surgeons to advanced tools, and driving sustainable growth through strategic initiatives.

Alphatec (ATEC) excels in Q3 earnings, eyes growth opportunities

Alphatec (ATEC) reported a robust Q3 performance marked by strong revenue growth and positive adjusted EBITDA, driven by surgical and EOS revenue increases. While challenges in gross margin and cash flow breakeven exist, the company remains optimistic about long-term financial commitments and revenue growth. ATEC's strategic focus on value creation, surgeon adoption, and innovation positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q1 2020 Results - Earnings Call Transcript

CARLSBAD, Calif., April  27, 2020  (GLOBE NEWSWIRE) --  Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has terminated the Tender Offer Agreement (“TOA”), dated February 26, 2020, under which it was to acquire EOS imaging, SA (“EOS”), for up to $88 million, plus debt retirement of $33.9 million, in a combination of cash and equity.

ATEC Terminates Agreement to Acquire EOS Imaging

CARLSBAD, Calif., April  08, 2020  (GLOBE NEWSWIRE) --  Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today preliminary revenue results for the first quarter ended March 31, 2020, and provided a business update on its response to the COVID-19 pandemic.

ATEC Announces Preliminary First Quarter 2020 Revenue Results And Provides Business Update

Alphatec Holdings has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Alphatec Holdings Enters Oversold Territory

Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q4 2019 Results - Earnings Call Transcript

CARLSBAD, Calif., Feb.  28, 2020  (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has entered into an agreement to acquire EOS imaging, SA, for a purchase price of up to $88 million, plus debt retirement of $33.9 million, in a combination of cash and equity.

ATEC Announces Agreement to Acquire EOS imaging 

ACM Research

Aspen Aerogels

Intelligent Systems

Orion Energy Systems

Roku

These aggressive stocks to buy have had roaring success in the last year and are set to continue gaining in 2020.

7 Exciting Stocks to Buy for Aggressive Investors

BioDelivery Sciences

BioXcel Therapeutics

Amicus Therapeutics

Geron

Inovio Pharmaceuticals

Insmed

When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.

7 Healthcare Stocks With 100% Street Support

CARLSBAD, Calif., Jan.  13, 2020  (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today preliminary revenue results for the fourth quarter and full year ended December 31, 2019, and provided revenue guidance for the full year 2020.

ATEC Announces Preliminary 2019 Revenue Results and 2020 Revenue Outlook

Automated Technology Detects Location and Monitors Health of Nerves During Spine Surgery Automated Technology Detects Location and Monitors Health of Nerves During Spine Surgery

ATEC Announces Commercial Launch of the SafeOp Neural InformatiX System™

Alphatec Holdings, Inc. (ATEC) CEO Pat Miles on Q3 2019 Results - Earnings Call Transcript

CARLSBAD, Calif., Oct.  22, 2019  (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today the commercial release of its porous titanium line of IdentiTi™ implants for lateral interbody fusion (LIF) procedures. The launch of the IdentiTi LIF Interbody Implant Systems follows successful alpha evaluations that began in January 2019. The Company has successfully commercialized all of the six IdentiTi Implant Systems slated for release in 2019.

Alphatec Enhances its Lateral Portfolio With the Commercial Launch of Approach-Specific Innovation

CARLSBAD, Calif., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today the commercial release of its IdentiTi TLIF Posterior Oblique Titanium Interbody Implant System (“IdentiTi PO”) for transforaminal lumbar interbody fusion procedures.  The launch of IdentiTi (TLIF) PO follows successful alpha evaluations that began in January 2019 and marks the fifth of six IdentiTi Implant Systems to be launched this year by ATEC’s Organic Innovation Machine™.

Alphatec Announces Commercial Launch of IdentiTi™ TLIF Posterior Oblique Porous Titanium Interbody Implant System

EVP, People/Culture & GC of Alphatec Holdings Inc (30-Year Financial, Insider Trades) Craig E Hunsaker (insider trades) sold 100,000 shares of ATEC on 08/12/2019 at an average price of $5.88 a share.

Alphatec Holdings Inc (ATEC) EVP, People/Culture & GC Craig E Hunsaker Sold $588,000 of Shares

Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q2 2019 Results - Earnings Call Transcript

Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alphatec (ATEC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Avon Products

Companhia Siderurgica Nacional

These low-priced stocks are trading at new highs and could add to gains in coming weeks.

3 Cheap Stocks Hitting New Highs

Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q1 2019 Results - Earnings Call Transcript

The stock was a poor performer in Q4 but experienced an impressive bounce in Q1.

News for Alphatec Hlds Stock (ATEC)